
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Kisunla (donanemab-azbt, 350mg/20ml once-monthly injection for …
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions

